Resected adenocarcinoma of the pancreas— 616 patients: Results, outcomes, and prognostic indicators
By T. Sohn, C. Yeo, J. Cameron, L. Koniaris, S. Kaushal, R. Abrams, P. Sauter, J. Coleman, R. Hruban, K. Lillemoe. Journal of Gastrointestinal Surgery, 2000
1,508 citations recorded by the source corpus.
Subfields: Epidemiology, Oncology, Surgery
View Paper: https://www.semanticscholar.org/paper/f78452bd189f8266054da57f5299972526795658
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. (2009, background): “Thus, 80% of patients with pancreatic cancer have advanced stage disease at diagnosis and are not candidates for surgical intervention.(2,3) A recent study indicated an alarming reluctance in the medical community to proceed to potentially curative surgery in patients with early-stage pancreatic can”
- Advanced pancreatic carcinoma: current treatment and future challenges (2010, background): “Perineural, vascular and lymphatic invasion are commonly observed in resected tumor specimens; lymph-node metastases are present in 50–75% of resected cases”
- Pancreatic ductal adenocarcinoma: Long-term survival does not equal cure (2012, neutral): “Variable Long-term survivors (overall), n (%) (n = 95) ≥5- and <10-year survivorship, n (%) (n = 62) ≥10-yr survivorship, n (%) (n = 33) Chi-square P-value Gender NS Female 42 (45) 30 (48) 12 (37) Male 53 (55) 32 (52) 21 (63) Tumor location NS Head 77 (81) 51 (82) 26 (79) Body 7 (7) 5 (8) 2 (6) Tail”
- A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma (2010, background): “Previous studies in PDAC have found that nodal status is the most predictive of outcome for patients with localized PDAC [37].”
- Intraductal Papillary Mucinous Neoplasms of the Pancreas: An Updated Experience (2004, methodology): “The 5-year survival rate of 43% for those with resected invasive adenocarcinoma is similar to that seen in other series of IPMNs(2,8,17) and is better than the 15% to 25% 5-year survival typically reported for resected invasive ductal adenocarcinoma of the pancreas.(7,19) The presence of invasive ca”
- A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. (2004, neutral): “(%) No Yes Unknown 101 (70) 29 (20) 15 (10) 102 (71) 30 (21) 12 (8) 106 (72) 24 (16) 17 (12) 97 (68) 35 (25) 10 (7) 203 (70) 59 (20) 27 (9)”